Novel Approach to Continuation of Elective Procedures in People at Risk for Sodium–Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Ketoacidosis

Diabetes is a common comorbidity among people undergoing elective procedures ranging from screening colonoscopies (1) to joint replacements (2). Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a relatively new class of diabetes pharmacotherapy that help to achieve glycemic control by inhibiting glucose reabsorption in renal tubules (3). The U.S. Food and Drug Administration (FDA) has approved five SGLT2 inhibitors for type 2 diabetes to be used as stand-alone monotherapies or in combination with other pharmacotherapies (4).